A Message from Financial Markets Daily 
NV-387 could be a single drug to treat all of the "tripledemic" viruses and more! The success of penicillin led to an explosion in the development of antibacterials. But what about fighting viruses? One NYSE-traded biotech company is on a solid footing to revolutionize the treatment of antiviral infections with game-changing antiviral nanomedicines. These drugs could be as revolutionary as antibiotics and do not rely on immune systems making them great for seniors and children! The company’s lead drug candidate NV-387 is aimed to treat RSV, Covid-19, Long Covid, Influenza, Bird Flu H5N1, and other respiratory viral infections. NV-387 was substantially superior to the three approved drugs, namely Tamiflu®, Rapivab® , and Xofluza® against an Influenza H3N2 lethal lung viral infection study. The company believes that NV-387 is expected to possess strong antiviral activity against H5N1 "Bird Flu" as well, given that H5N1 viruses are known to bind to heparan sulfate proteoglycans, and based on the observed broad-spectrum activity of NV-387. NV-387 was also at least as good as TPOXX® in a model animal study for the development of Smallpox/Mpox drugs, in two different ways of acquiring infection. Additionally, it has been found that NV-387 is capable of completely curing a lethal RSV lung virus infection in animals, leading to indefinite survival of the animals, as reported recently. There is no cure for RSV, and no approved drug for treatment of RSV infection other than the toxic last-resort drug ribavirin! See how NV-387 could be highly valuable for preparedness against novel viral epidemics and pandemics all while building shareholder value for this growing biotech company. |
